期刊
EUROPEAN HEART JOURNAL
卷 36, 期 24, 页码 1512-U92出版社
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehv114
关键词
Heme oxygenase pathway; Carbon monoxide; Bilirubin; Biliverdin; Cardiovascular disease
资金
- Ellison Foundation
- NIH/NHLBI [R01HL114839, R03HL115106, P01HL108801, R00HL107642]
Evidence now points to the haeme oxygenase (HO) pathway as a possible actor in modulating risk for cardiovascular disease (CVD). In particular, the HO pathway may represent a key endogenous modulator of oxidative, inflammatory, and cytotoxic stress while also exhibiting vasoregulatory properties. In this review, we summarize the accumulating experimental and emerging clinical data indicating how activity of the HO pathway and its products may play a role in mechanisms underlying the development of CVD. We also identify gaps in the literature to date and suggest future directions for investigation. Because HO pathway activity can be influenced not only by genetic traits and environmental stimuli but also by a variety of existing pharmacologic interventions, the pathway could serve as a prime target for reducing the overall burden of CVD. Further work is needed to determine the role of HO pathway products as possible prognostic markers of risk for clinical CVD events and the extent to which therapeutic augmentation or inhibition of HO pathway activity could serve to modify CVD risk.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据